Tag Archives: Christopher Marai

Deciphera Pharmaceuticals Inc (DCPH) Received its Third Buy in a Row

After Deutsche Bank and J.P. Morgan gave Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) a Buy rating last month, the company received another Buy, this time from Nomura. Analyst Christopher Marai maintained a Buy rating on Deciphera Pharmaceuticals Inc yesterday and set

Nomura Keeps a Buy Rating on Marker Therapeutics Inc (MRKR)

Nomura analyst Christopher Marai maintained a Buy rating on Marker Therapeutics Inc (MRKR – Research Report) on August 9 and set a price target of $16. The company’s shares closed last Monday at $4.50, close to its 52-week low of

Voyager Therapeutics Inc (VYGR) Gets a Buy Rating from Nomura

Nomura analyst Christopher Marai maintained a Buy rating on Voyager Therapeutics Inc (VYGR – Research Report) on August 9 and set a price target of $37. The company’s shares closed last Monday at $20.11. Marai observed: “Minor Tweaks Post-NBIX Collab.,

Nomura Thinks CytomX Therapeutics Inc’s Stock is Going to Recover

In a report issued on August 8, Christopher Marai from Nomura maintained a Buy rating on CytomX Therapeutics Inc (CTMX – Research Report), with a price target of $22. The company’s shares closed on Friday at $10.15, close to its

Nomura Sticks to Their Buy Rating for Protagonist Therapeutics (PTGX)

In a report issued on August 7, Christopher Marai from Nomura maintained a Buy rating on Protagonist Therapeutics (PTGX – Research Report), with a price target of $29. The company’s shares closed on Friday at $9.42. According to TipRanks.com, Marai

Nomura Believes Syndax Pharmaceuticals Inc (NASDAQ: SNDX) Won’t Stop Here

In a report issued on August 7, Christopher Marai from Nomura maintained a Buy rating on Syndax Pharmaceuticals Inc (SNDX – Research Report), with a price target of $16. The company’s shares closed on Friday at $9.89, close to its